The Evolution of MASLD Through an Endocrine Lens: Nomenclature Changes, Risk Stratification and Emerging Therapies

In this CME, Bhanvi Ramchandani, MD, reviews the evolution of MASH/MASLD nomenclature, disease spectrum, risk factors, and links to Type II diabetes. She also reviews evidence-based diagnosis, risk stratification, referral guidelines, and current and emerging therapies, including FDA-approved Resmetirom.

Educational Objectives 

Upon completion of this activity, participants should be able to:

1. Explain the Evolution of MASH/MASLD Nomenclature and spectrum of disease
2. Describe the risk factors, pathophysiology and association with Type II Diabetes Mellitus
3. Apply evidence-based recommendations for MASLD/MASH diagnosis, risk stratification, and referral to specialist care
4. Explain the current and Emerging Therapies for MASLD including FDA-Approved Therapy: Resmetirom (THR-beta Agonist)

Disclosures:

No members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Accreditation Statement:

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Pittsburgh designates enduring material activity for a maximum of 1.00 AMA PRA Category 1 Credit[s]™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

For your credit transcript, please access our website 4 weeks post-completion at http://ccehs.upmc.com and follow the link to the Credit Transcript page. If you do not provide the last 5 digits of your SSN on the next page you will not be able to access a CME credit transcript. Providing your SSN is voluntary.

Release Date: 4/21/2025 | Last Modified On: 4/21/2025 | Expires: 4/21/2026